London, Jan 19 (IANS) A team of Swiss researchers has identified that the complement system, a part of the body’s immune system, plays an important role in long Covid.
Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of manifestations.
Long Covid’s causes and disease mechanisms are still unknown, and there are no diagnostic tests or targeted treatments.
The study by the University of Zurich (UZH) in Switzerland pinpointed the role of the complement system — part of the innate immune system which normally helps to fight infections and eliminate damaged and infected body cells.
“In patients with long Covid, the complement system no longer returns to its basal state, but remains activated and, thus, also damages healthy body cells,” said Onur Boyman, professor of immunology at UZH.
In the study, published in the journal Science, the researchers followed 113 Covid patients for up to one year after their acute SARS-CoV-2 infection and compared them with 39 healthy controls.
After six months, 40 patients had active long Covid disease. More than 6,500 proteins in the blood of the study participants were analysed both during the acute infection and six months later.
“The analyses of which proteins were altered in long Covid confirmed the excessive activity of the complement system. Patients with active long Covid disease also had elevated blood levels indicating damage to various body cells, including red blood cells, platelets, and blood vessels,” explained Carlo Cervia-Hasler, a postdoctoral researcher in Boyman’s team.
The measurable changes in blood proteins in active long Covid indicate an interaction between proteins of the complement system, which are involved in blood clotting and the repair of tissue damage and inflammation.
In contrast, the blood levels of long Covid patients, who recovered from the disease, returned to normal within six months. Active long Covid is therefore characterised by the protein pattern in the blood.
“Our work not only lays the foundation for better diagnosis, but also supports clinical research into substances that could be used to regulate the complement system. This opens up new avenues for the development of more targeted therapies for patients with long Covid,” Boyman said.